Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ZIOPHARM Oncology Inc.    ZIOP

ZIOPHARM ONCOLOGY INC. (ZIOP)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

ZIOPHARM to Present at the Stifel 2017 Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 10:06pm CET

BOSTON, Nov. 10, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that David Mauney, M.D., CBO and interim COO, will present at the Stifel 2017 Healthcare Conference in New York on Tuesday, November 14, 2017 at 11:00 a.m. ET.

To access a live audio webcast of the presentation, please visit the Investor Relations section at www.ziopharm.com. The webcast will be archived for 90 days.

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing innovative gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® (RTS®) technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.

Contact:
David Pitts
Argot Partners
212-600-1902
[email protected]


© GlobeNewswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ZIOPHARM ONCOLOGY INC.
02:17p ZIOPHARM ONCOLOGY : Presents Positive Updated Results of Ad-RTS-hIL-12 Study in ..
11/20 ZIOPHARM ONCOLOGY : Trumpets “Positive” Results, But Shares Drop
11/20 ZIOPHARM ONCOLOGY : Presents Positive Updated Results of Ad-RTS-hIL-12 Study in ..
11/17 ZIOPHARM ONCOLOGY TO HOST CONFERENCE : 15 a.m. ET to Discuss Updated Clinical Da..
11/10 ZIOPHARM to Present at the Stifel 2017 Healthcare Conference
11/09 ZIOPHARM ONCOLOGY : Announces Four Presentation Abstracts at the 2017 Annual Mee..
11/07 ZIOPHARM ONCOLOGY : Announces Five Abstracts Accepted for Presentation at the 20..
11/06 ZIOPHARM ONCOLOGY : reports 3Q loss
11/06 ZIOPHARM ONCOLOGY INC : Results of Operations and Financial Condition, Change in..
11/06 ZIOPHARM ONCOLOGY : Management's Discussion and Analysis of Financial Condition ..
More news
News from SeekingAlpha
11/21 ZIOPHARM Oncology (ZIOP) Reports Positive Upadte Results of Ad-RTS-hIL-12 Stu..
11/21 YOUR DAILY PHARMA SCOOP : Roche Rallies, Alnylam Granted BTD, Celsion Soars
11/20 Ziopharm gives up early gains
11/20 YOUR DAILY PHARMA SCOOP : Geron's Fate, Celldex Commences Mid-Stage Study, Novar..
11/20 PREMARKET GAINERS AS OF 9 : 05 am
Financials ($)
Sales 2017 6,39 M
EBIT 2017 -54,9 M
Net income 2017 -76,0 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 94,7x
Capi. / Sales 2018 112x
Capitalization 605 M
Chart ZIOPHARM ONCOLOGY INC.
Duration : Period :
ZIOPHARM Oncology Inc. Technical Analysis Chart | ZIOP | US98973P1012 | 4-Traders
Technical analysis trends ZIOPHARM ONCOLOGY INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 12,5 $
Spread / Average Target 193%
EPS Revisions
Managers
NameTitle
Laurence James Neil Cooper Chief Executive Officer
David M. Mauney Executive VP, Chief Operating & Business Officer
Kevin G. Lafond Principal Financial Officer & Treasurer
Francois Lebel Chief Medical Officer, EVP-Research & Development
Murray F. Brennan Lead Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ZIOPHARM ONCOLOGY INC.-14.58%605
GILEAD SCIENCES1.16%94 693
REGENERON PHARMACEUTICALS6.67%41 304
VERTEX PHARMACEUTICALS100.10%36 699
GENMAB4.43%11 899
EXELIXIS, INC.76.93%7 707